To maximize the potential for Etna Biotech’s technologies and to enhance the prospects of its R&D pipeline, the company has established a strong network of partnerships. Current R&D collaborations include partnerships with:

• Istituto Superiore di Sanita, Italy;

• National Institute of Allergy and Infectiouse Diseases – NIH, US;

• Infectious Disease Research Institute, US;

• Instituto de Biologia Molecular e Cellular (IBMC), Portugal;

• Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid, Spain;

• Swiss Tropical and Public Health Institute, Switzerland;

• Meditox Sro, Czech Republic;

• European Vaccine Initiative, Germany;

• Biomedical Primate Research Centre (BPRC), The Netherlands

• Central Veterinary Institute, The Netherlands;

• Instituto de Biologia Experimental e Tecnológica (iBET), Portugal;

• National Institute for Biological Standards and Control (NIBSC), a centre of the Medicine and Healthcare Products Regulatory Agency (MHRA), United Kingdom;

• Redbiotec AG (RBT), Switzerland;

• University of Wien, Austria;

• University of Catania, Italy;

• Softeco Sismat SpA, Italy;

• National Council of the Research, Italy;

• Scientific and Techonology Park of the Sicily, Italy;

• Agroindustry Advanced Technologies S.p.A., Italy;

• Johns Hopkins University, US;

• The University of Sheffield, United Kingdom;

• Archivel Farma, Spain;

• Stichting Tuberculosis Vaccine Initiative (TBVI), The Netherlands;

• The All India Institute of Medical Sciences (AIIMS), India.

• University of Bologna, Italy.